Phio Pharmaceuticals Corp

Financials

Cash from operating activities -8.8 M-11.86 M-12.13 M-10.75 M-7.11 M-7.98 M -7.98 M Cash from investing activities -19 K-51 K-121 K-5 0008 000-12 K -12 K Cash from financing activities 16.13 M21.72 M-26 K7.41 M4 M23.64 M 23.64 M Free cash flow -8.82 M-11.91 M-12.25 M-10.75 M-7.11 M-7.99 M -7.99 M

Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.

PHIO

Financials

Phio Pharmaceuticals Corp

Notícias

Phio Pharmaceuticals apresentará dados de ensaio clínico do PH-762 na sexta-feira

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Phio Pharma (NASDAQ:PHIO)

Ações da Phio Pharmaceuticals disparam após resultados positivos de tratamento contra câncer

Phio Pharmaceuticals stock soars after strong cancer treatment results

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Phio Pharma (NASDAQ:PHIO)

Phio Pharmaceuticals relata taxa de resposta de 70% em estudo de câncer de pele

Phio Pharmaceuticals reports 70% response rate in skin cancer trial

Presidente da Phio Pharmaceuticals, Bitterman, compra US$ 5.100 em ações

Phio inicia estudo toxicológico exigido pelo FDA para medicamento contra câncer PH-762

Phio to begin FDA-required toxicology study for cancer drug PH-762

Phio completa recrutamento em ensaio de Fase 1b para terapia contra câncer de pele

Phio completes enrollment in Phase 1b trial of skin cancer therapy